BR0015872A - Agentes antitrombóticos - Google Patents

Agentes antitrombóticos

Info

Publication number
BR0015872A
BR0015872A BR0015872-0A BR0015872A BR0015872A BR 0015872 A BR0015872 A BR 0015872A BR 0015872 A BR0015872 A BR 0015872A BR 0015872 A BR0015872 A BR 0015872A
Authority
BR
Brazil
Prior art keywords
antithrombotic agents
agents
antithrombotic
antitrombotic
monoclonal antibodies
Prior art date
Application number
BR0015872-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Frank C Barone
Michael N Blackburn
Giora Z Feuerstein
John R Toomey
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of BR0015872A publication Critical patent/BR0015872A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
BR0015872-0A 2000-05-15 2000-10-05 Agentes antitrombóticos BR0015872A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57143400A 2000-05-15 2000-05-15
PCT/US2000/027438 WO2001087339A1 (en) 2000-05-15 2000-10-05 Antithrombotic agents

Publications (1)

Publication Number Publication Date
BR0015872A true BR0015872A (pt) 2004-08-03

Family

ID=24283688

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0015872-0A BR0015872A (pt) 2000-05-15 2000-10-05 Agentes antitrombóticos

Country Status (20)

Country Link
US (1) US20050037006A1 (enExample)
EP (2) EP1825864A3 (enExample)
JP (1) JP2004516236A (enExample)
KR (2) KR20070116192A (enExample)
CN (2) CN101134107A (enExample)
AT (1) ATE345816T1 (enExample)
AU (2) AU7858400A (enExample)
BR (1) BR0015872A (enExample)
CA (1) CA2411369A1 (enExample)
CZ (1) CZ20023778A3 (enExample)
DE (1) DE60032029T2 (enExample)
ES (1) ES2277597T3 (enExample)
HU (1) HU225874B1 (enExample)
IL (1) IL152831A0 (enExample)
MX (1) MXPA02011385A (enExample)
NO (1) NO20025463L (enExample)
NZ (1) NZ522632A (enExample)
PL (1) PL360060A1 (enExample)
WO (1) WO2001087339A1 (enExample)
ZA (1) ZA200209265B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8980952B2 (en) 2002-03-20 2015-03-17 University Of Maryland, Baltimore Methods for treating brain swelling with a compound that blocks a non-selective cation channel
PT2438913T (pt) 2002-03-20 2020-05-27 Us Veterans Affairs Canal de catiões não seletivos em células neurais e compostos que bloqueiam o canal para utilização no tratamento de edema cerebral
US7872048B2 (en) 2004-09-18 2011-01-18 University Of Maryland, Baltimore Methods for treating spinal cord injury with a compound that inhibits a NCCa-ATP channel
EP2359832A3 (en) 2004-09-18 2011-11-23 University of Maryland, Baltimore Therapeutic agents targeting the NCCA-ATP channel and methods of use thereof
EP3103451A1 (en) 2007-01-12 2016-12-14 University of Maryland, Baltimore Targetting ncca-atp channel for organ protection following ischemic episode
CA2974689C (en) 2007-06-22 2020-02-25 The United States Of America As Represented By The Department Of Veters Affairs Inhibitors of ncca-atp channels for therapy
DK2202245T3 (en) 2007-09-26 2016-11-21 Chugai Pharmaceutical Co Ltd A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR
AU2008326348B2 (en) * 2007-11-21 2014-01-30 Oregon Health & Science University Anti-factor XI monoclonal antibodies and methods of use thereof
US9518128B2 (en) 2011-12-14 2016-12-13 Janssen Pharmaceuticals, Inc. Thrombin-binding antibody molecules
GB201121513D0 (en) * 2011-12-14 2012-01-25 Cambridge Entpr Ltd Thrombin-binding antibody molecules and uses thereof
US20200231701A1 (en) * 2016-12-23 2020-07-23 Novartis Ag Methods of treatment with anti-factor xi/xia antibodies
WO2018199214A1 (ja) 2017-04-27 2018-11-01 中外製薬株式会社 薬物動態が改善された血液凝固第ｉｘ因子
US20240018503A1 (en) * 2017-04-27 2024-01-18 Chugai Seiyaku Kabushiki Kaisha Coagulation factor ix with improved pharmacokinetics
CN115448985A (zh) * 2021-06-08 2022-12-09 上海循曜生物科技有限公司 新型抗栓抗体

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2049655C (en) * 1990-09-17 1996-11-12 Akio Odawara Pharmaceutical composition for inhibiting platelet aggregation
MA24512A1 (fr) * 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose
WO2000007626A1 (en) * 1998-08-07 2000-02-17 Smithkline Beecham Corporation Use of anti-coagulation factor antibodies as long-lasting protective agents
AU766551C (en) * 1998-08-28 2005-02-17 Genentech Inc. Human anti-factor IX/IXa antibodies

Also Published As

Publication number Publication date
NO20025463D0 (no) 2002-11-14
EP1282444A4 (en) 2004-06-30
DE60032029D1 (de) 2007-01-04
DE60032029T2 (de) 2007-05-31
CN1501812A (zh) 2004-06-02
EP1282444B1 (en) 2006-11-22
EP1282444A1 (en) 2003-02-12
AU7858400A (en) 2001-11-26
JP2004516236A (ja) 2004-06-03
HUP0301804A2 (hu) 2003-08-28
US20050037006A1 (en) 2005-02-17
WO2001087339A1 (en) 2001-11-22
IL152831A0 (en) 2003-06-24
CZ20023778A3 (cs) 2003-08-13
EP1825864A3 (en) 2007-09-12
MXPA02011385A (es) 2004-01-26
CN100339132C (zh) 2007-09-26
NZ522632A (en) 2005-05-27
KR20070116192A (ko) 2007-12-06
CN101134107A (zh) 2008-03-05
ATE345816T1 (de) 2006-12-15
HU225874B1 (en) 2007-11-28
NO20025463L (no) 2003-01-09
KR20030034071A (ko) 2003-05-01
ZA200209265B (en) 2003-10-22
AU2000278584B2 (en) 2006-11-16
ES2277597T3 (es) 2007-07-16
PL360060A1 (en) 2004-09-06
HUP0301804A3 (en) 2005-12-28
CA2411369A1 (en) 2001-11-22
EP1825864A2 (en) 2007-08-29

Similar Documents

Publication Publication Date Title
EA200300464A1 (ru) ГУМАНИЗИРОВАННОЕ АНТИТЕЛО ПРОТИВ РЕЦЕПТОРА ЛИМФОТОКСИНА-β (ВАРИАНТЫ), КОМПОЗИЦИЯ, СПОСОБ ЛЕЧЕНИЯ ИЛИ СНИЖЕНИЯ РИСКА РАЗВИТИЯ, ТЯЖЕСТИ ИЛИ ПОСЛЕДСТВИЙ НЕОПЛАЗИИ У ЧЕЛОВЕКА, ВЫДЕЛЕННАЯ НУКЛЕИНОВАЯ КИСЛОТА (ВАРИАНТЫ), КЛЕТКА КЛЕТОЧНОЙ ЛИНИИ
UY3402Q (es) Diseno de tractor
SV2001000288A (es) 3- aminoquinazolin - 2, 4 - dione agentes antibacteriales
DE60010098D1 (de) 28-epirapaloge
DK1189634T3 (da) Behandling af prostatacancer med anti-ErbB2-antistoffer
UY3450Q (es) Botella
ATE415979T1 (de) Behandlung mit anti-erbb2 antikörpern
UY3441Q (es) Cepillo de dientes
DK1985626T3 (da) P. gingivalis-antigensammensætning
BR0015872A (pt) Agentes antitrombóticos
DOP2001000219A (es) Applicator
EA200100854A1 (ru) Кальций-литические соединения
UA94211C2 (ru) Выделенное полностью человеческое моноклональное cd3 антитело
DE60139694D1 (de) Menschliche myelom zelllinie
EA200200798A1 (ru) Кальцилитические соединения
TR200200926T2 (tr) Isıyla şekillendirilebilen poliamidler.
FI20011055A0 (fi) Heveiiniä sitovat monoklonaaliset vasta-aineet
EP1252190A4 (en) PROTEIN-SPECIFIC ANTIBODIES HAVING POLYGLUTAMINE EXPANSIONS
PT1318800E (pt) 1-aminoalquilciclo-hexanos como agentes tripanocidas
ITPD20000192A0 (it) Anticorpi policlonali
UA50030A (uk) Комплексне добриво
ATE535259T1 (de) Immunogener, monoklonaler antikörper
AR028262A1 (es) Anticuerpos especificos de fap-alfa humanos
JO2151B1 (en) Toilet (T.S)
DOP2002000329A (es) Composicion solida

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A E 10A ANUIDAD(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2073 DE 28/09/2010.